{
    "2020-09-14": [
        [
            {
                "time": "2023-10-15",
                "original_text": "Novartis Reports Positive Data on Beovu for DME Indication",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Beovu",
                        "Positive",
                        "DME",
                        "Indication"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "European Medicines Agency Approves Safety Label Update For Novartis' Beovu - Quick Facts",
                "features": {
                    "keywords": [
                        "European Medicines Agency",
                        "Safety",
                        "Label",
                        "Update",
                        "Novartis",
                        "Beovu"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "regulatory"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "European Medicines Agency (EMA) approves safety label update for Novartis Beovu®",
                "features": {
                    "keywords": [
                        "EMA",
                        "Safety",
                        "Label",
                        "Update",
                        "Novartis",
                        "Beovu"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "regulatory"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Novartis aims to expand Beovu use after safety fears hurt launch",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Beovu",
                        "Expand",
                        "Safety",
                        "Fears",
                        "Launch"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Novartis says Beovu matched rival Eylea in visual acuity in eye disease",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Beovu",
                        "Eylea",
                        "Visual Acuity",
                        "Eye Disease"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Beovu",
                        "Phase III",
                        "Trial",
                        "Aflibercept",
                        "DME"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "clinical trials"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}